# Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

> **NCT05485207** · EARLY_PHASE1 · UNKNOWN · sponsor: **Stanford University** · enrollment: 5 (actual)

## Conditions studied

- Interstitial Cystitis
- Bladder Pain Syndrome

## Interventions

- **DRUG:** Transvaginal botulinum toxin A (BTA) injection

## Key facts

- **NCT ID:** NCT05485207
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-04
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05485207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05485207, "Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05485207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*